RecruitingPhase 3

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

United States450 participantsStarted 2025-05-19

Plain-language summary

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Donation after Circulatory Death (DCD) donor
✓. High-risk Donation after Brain Death (DBD) donor

What they're measuring

Time to Freedom from Dialysis

Timeframe: Through 90 days post-transplant

Trial details

NCT IDNCT06830798

SponsorAlexion Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-02-04

Contact for this trial

Alexion Pharmaceuticals, Inc. (Sponsor)

1-855-752-2356 clinicaltrials@alexion.com

View on ClinicalTrials.gov More Delayed Graft Function trials